- A Combination of Melphalan, Prednisone, and 50 mg Thalidomide Treatment in Non-Transplant-Candidate Patients with Newly Diagnosed Multiple Myeloma
-
Chang HJ, Lee JH, Do YR, Bae SH, Lee JL, Nam SH, Yoon SS, Bang SM
- KMID: 1729242
- Korean J Intern Med.
- 2011 Dec;26(4):403-409.
- doi: 10.3904/kjim.2011.26.4.403
BACKGROUND/AIMS: The clinical efficacy and safety of a three-drug combination of melphalan, prednisone, and thalidomide were assessed in patients with multiple myeloma who were not candidates for high-dose therapy as... -
- CITED
-
- Close
- SHARE
-
- Close
- Early Response to Bortezomib Combined Chemotherapy Can Help Predict Survival in Patients with Multiple Myeloma Who Are Ineligible for Stem Cell Transplantation
-
Lee HS, Kim YS, Kim K, Kim JS, Kim HJ, Min CK, Suh C, Eom HS, Yoon SS, Lee JH, Kim MK, Kim SH, Bae SH, Mun YC, Jo DY, Chung JS, The Korean Multiple Myeloma Working Party (KMMWP)
- KMID: 2158005
- J Korean Med Sci.
- 2013 Jan;28(1):80-86.
- doi: 10.3346/jkms.2013.28.1.80
Novel agents to treat multiple myeloma (MM) have increased complete respone (CR) rates compared with conventional chemotherapy, and the quality of the response to treatment has been correlated with survival.... -
- CITED
-
- Close
- SHARE
-
- Close
